Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Phase 3 Recruiting 194 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

Timeline

Start: 2025-04-08
Primary completion: 2031-04-11
Completion: 2036-07-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Fingolimod	Small molecule	—	Oral
Subject	Ozanimod	Small molecule	—	Oral

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Summary

Timeline

Drugs

Indications